Hepatican Ltd Invited to present at Oxford Globals’ flagship event Cell 2025

Hepatican Ltd founder and UCL Professor Clare Selden, was invited to speak at Oxford Globals’ Cell 2025 event, taking place on 11th-12th November, 2025, in London. Cell 2025, recognised as one of the premier global gatherings in the cell culture, cell & gene therapy, and advanced therapy landscape, brought together innovators, industry leaders, regulators and clinicians from across pharma, biotech and academic sectors to explore cutting-edge developments from discovery through commercialisation.

Hepatican Ltd delivered two standout presentations that spanned both scientific depth and commercial insight. The first, entitled “A Combined ATMP & Medical Device for Patients with Liver Failure: An Academic’s Path from Basic Science to Translational Medicine,” traced the rigorous academic research that underpins the company’s bio-artificial liver system. Drawing on more than two decades of foundational work, the talk highlighted how basic science discoveries are being translated into a tangible therapeutic option for a condition with a significant unmet need.

In a second session, Hepatican articulated the urgent clinical demand for effective liver support therapies and made a compelling case for the commercial viability of its technology. The presentation outlined the global burden of liver failure, potential market opportunities, and strategic pathways to adoption that would benefit patients, healthcare systems, and investors alike.

Cell 2025’s comprehensive programme of keynote speeches, technical talks and investor showcases provided a high-profile stage for Hepatican to position itself among the field’s most promising innovators.